Serum concentrations and expressions of serum amyloid A and leptin in adipose tissue are interrelated: The Genobin Study

European Journal of Endocrinology

Volumn 158, Issue 3, 2008, Pages 333-341

  Lappalainen, Tiina ^a   Kolehmainen, M ^a   Schwab, U ^a,b   Pulkkinen, L ^a   Laaksonen, D E ^a,b   Rauramaa, R ^a   Uusitupa, M ^a   Gylling, H ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; GLUCOSE; LEPTIN; MESSENGER RNA;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BODY MASS; CELL SIZE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT CONTROL; WEIGHT REDUCTION;

ADIPOCYTES; ADIPOSE TISSUE; AGED; BODY WEIGHT; FEMALE; GENE EXPRESSION; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; WEIGHT LOSS;

EID: 40949098985     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0598     Document Type: Article

References (34)

1. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiologica Scandinavica 2005 184 285-293.
2. Tilg H & Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews. Immunology 2006 6 772-783.
3. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE & Schauer PR. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obesity Surgery 2004 14 589-600.
4. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, Stich V, Cancello R & Langin D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB Journal 2004 18 1657-1669.
5. Gomez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalan V, Rodriguez A, Jesus Gil M & Fruhbeck G. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obesity Surgery 2006 16 262-269.
6. Poitou C, Coussieu C, Rouault C, Coupaye M, Cancello R, Bedel JF, Gouillon M, Bouillot JL, Oppert JM, Basdevant A & Clément K. Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status. Obesity 2006 14 309-318.
7. Salas-Salvado J, Bullo M, Garcia-Lorda P, Figueredo R, Del Castillo D, Bonada A & Balanzà R. Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss. International Journal of Obesity 2006 30 1714-1720.
8. Sjöholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, Lystig TC, Jennische E, Brandberg J, Torgerson JS, Carlsson B & Carlsson LM. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. Journal of Clinical Endocrinology and Metabolism 2005 90 2233-2239.
9. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE & National Heart, Lung, and Blood Institute. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004 109 726-732.
10. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI & Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997 96 2914-2919.
11. Kisilevsky R & Tam SP. Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. Pediatric Pathology and Molecular Medicine 2002 21 291-305.
12. Steinmetz A, Hocke G, Saile R, Puchois P & Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochimica et Biophysica Acta 1989 1006 173-178.
13. Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, Stich V, Coussieu C, Gauthier E, Courtine M, Zucker JD, Barsh GS, Saris W, Bruneval P, Basdevant A, Langin D & Clément K. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005 48 519-528.
14. Friedman JM & Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998 395 763-770.
15. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA & Friedman JM. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Medicine 1995 1 1155-1161.
16. Montague CT, Prins JB, Sanders L, Digby JE & O'Rahilly S. Depot-and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997 46 342-347.
17. van Dielen FM, van't Veer C, Schols AM, Soeters PB, Buurman WA & Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. International Journal of Obesity and Related Metabolic Disorders 2001 25 1759-1766.
18. Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gomez-Reino J & Gualillo O. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology 2006 45 944-950.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001 285 2486-2497.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA & Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung, and Blood Institute scientific statement. Current Opinion in Cardiology 2006 21 1-6.
21. Bergman RN. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989 38 1512-1527.
22. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM & Bergman RN. MINMOD millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technology and Therapeutics 2003 5 1003-1015.
23. Ohisalo JJ, Kaartinen JM, Ranta S, Mustajoki P, Hreniuk SP, LaNoue KF & Martin LF. Weight loss normalizes the inhibitory effect of N6-(phenylisopropyl)adenosine on lipolysis in fat cells of massively obese human subjects. Clinical Science 1992 83 589-592.
24. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. Journal of Biological Chemistry 1964 239 375-380.
25. Thorn CF, Lu ZY & Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scandinavian Journal of Immunology 2004 59 152-158.
26. Santos-Alvarez J, Goberna R & Sanchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cellular Immunology 1999 194 6-11.
27. Fried SK, Bunkin DA & Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. Journal of Clinical Endocrinology and Metabolism 1998 83 847-850.
28. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB & Reis SE. National Heart, Lung, and Blood Institute. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004 109 726-732.
29. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A & Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001 104 3052-3056.
30. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD & Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. Journal of the American College of Cardiology 2004 44 1819-1824.
31. Abdullah SM, Khera A, Leonard D, Das SR, Canham RM, Kamath SA, Vega GL, Grundy SM, McGuire DK & de Lemos JA. Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis 2007 195 404-410.
32. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, Berger PB & Somers VK. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004 109 2181-2185.
33. Kazumi T, Kawaguchi A, Hirano T & Yoshino G. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 2003 52 1113-1116.
34. Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A, Amor IB, Staccini-Myx A, Huet PM, Gugenheim J, Sadoul JL, Le Marchand-Brustel Y, Tran A & Gual P. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. American Journal of Gastroenterology 2006 101 1824-1833.